Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 331

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 331
---
                                            and supply agreements;

●failure by us or our licensors to prosecute, maintain, or enforce
                                            our intellectual property rights;

●changes in laws or regulations applicable to our drug candidates;

●any inability to obtain adequate supply of our drug candidates
                                            or the inability to do so at acceptable prices;

●adverse regulatory authority decisions;

●introduction of new products, services or technologies by our
                                            competitors;

●failure to maintain the listing of our Common Stock on the Nasdaq
                                            Capital Market and the effects of any reverse stock split that we may complete in order to
                                            maintain this listing;

●failure to meet or exceed financial and development projections
                                            we may provide to the public;

●failure to meet or exceed the financial and development projections
                                            of the investment community;

●the perception of the pharmaceutical industry by the public,
                                            legislatures, regulators and the investment community;

●announcements of significant acquisitions, strategic collaborations,
                                            joint ventures or capital commitments by us or our competitors;

●disputes or other developments relating to proprietary rights,
                                            including patents, litigation matters, and our ability to obtain patent protection for our
                                            technologies;

●additions or departures of key personnel;

●significant lawsuits, including patent or stockholder litigation;

●failure by securities or industry analysts to publish research
                                            or reports about our business, or issuance of any adverse or misleading opinions by such
                                            analysts regarding our business or stock;

●changes in the market valuations of similar companies;

●general market or macroeconomic conditions, such as inflation;

●fluctuations of exchange rates between the U.S. dollar and the
                                            Australian dollar;

77

●sales or repurchases of our common stock by us or our stockholders
                                            in the future;

●the trading volume of our common stock;

●announcements by commercial partners or competitors of new commercial
                                            products, clinical progress or the lack thereof, significant contracts, commercial relationships
                                            or capital commitments;

●the introduction of technological innovations or new therapies
                                            that compete with our potential drugs;

●changes in the structure of healthcare payment systems;

●the impact of political instability and military conflicts, such
                                            as the conflicts and recent events in Ukraine and the Middle East, which has resulted in
                                            instability in the global financial markets and export controls; and

●period-to-period fluctuations in our financial results.

Moreover, the stock markets in general have experienced
substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market